Serving the Society Since 1986
Advanced Search
Volume 30 Issue 4
August 2015
    Citation: Tielong Chen, Yilan Hu, Quanquan Ding, Jing Yu, Fubing Wang, Fengling Luo, Xiao-Lian Zhang. Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases .VIROLOGICA SINICA, 2015, 30(4) : 249-260.  http://dx.doi.org/10.1007/s12250-015-3605-4
    shu

    Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases

    • 1.

      State Key Laboratory of Virology and Department of Immunology and Hubei Province Key Laboratory of Allergy and Immunology, Wuhan University School of Medicine, Wuhan 430071, China

    • 2.

      Zhongnan Hospital of Wuhan University, Wuhan 430071, China

    • 3.

      Department of Immunology, Wuhan University of Science and Technology School of Medicine, Wuhan 430065, China

    • 4.

      Hubei Cancer Hospital, Wuhan 430079, China

    • Corresponding author: Fengling Luo, fengling810810@163.com, ORCID: 0000-0003-0826-7327
      Xiao-Lian Zhang, zhangxiaolian@whu.edu.cn, ORCID: 0000-0002-8283-9381
    • Those authors contributed equally to this work.
    • Received Date: 08 May 2015
      Accepted Date: 13 July 2015
      Published Date: 23 July 2015
      Available online: 01 August 2015
    • Human ficolin-2 is an important lectin complement pathway activator that is secreted from liver cells and has been implicated as an anti-infection innate immune molecule. However, the role of ficolin-2 protein and its dynamic changes over the course of and in the prognosis of chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC) remain unclear. In this study, we analyzed ficolin-2 protein expression in a cohort of individuals with CHB infection, HCC and cirrhosis. A sandwich enzyme-linked immunosorbent assay (ELISA) method was used to measure serum ficolin-2 concentrations. Ficolin-2 expression in liver tissues was detected by immunohistochemical staining. Serum ficolin-2 concentrations in CHB patients were significantly higher than in healthy controls and HBV carriers. After 48 weeks of routine amelioration liver function treatment, serum ficolin-2 concentrations decreased and were positively correlated with favorable alanine aminotransferase (ALT), HBV DNA and HBeAg-seroconversion outcomes. Interestingly, we observed much lower expression of serum and intrahepatic ficolin-2 in HCC and cirrhosis compared with healthy controls. Our findings suggest that serum and intrahepatic ficolin-2 levels may be considered one of the indicators for the response of chronic HBV infection, HCC and cirrhosis.
    • 加载中

      1. Brown KS, Keogh MJ, Tagiuri N, Grainge MJ, Presanis JS, RyderSD, Irving WL, Ball JK, Sim RB, Hickling TP. 2007. Severefibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associatedserine protease 1 (MASP-1) complex. Clin Exp Immunol, 147: 90-98.

      2. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. 1994. Classification of chronic hepatitis: diagnosis, grading andstaging. Hepatology, 19: 1513-1520.
          doi: 10.1002/(ISSN)1527-3350

      3. Dunkelberger JR, Song WC. 2010. Complement and its role in innate and adaptive immune responses. Cell Res, 20: 34-50.
          doi: 10.1038/cr.2009.139

      4. Eisen DP, Minchinton RM. 2003. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis, 37:1496-1505.
          doi: 10.1086/379324

      5. El-Serag HB. 2012. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142: 1264-1273. e1261.
          doi: 10.1053/j.gastro.2011.12.061

      6. Endo Y, Sato Y, Matsushita M, Fujita T. 1996. Cloning and characterization of the human lectin P35 gene and its related gene. Genomics, 36: 515-521.
          doi: 10.1006/geno.1996.0497

      7. Esmat S, Omran D, Sleem GA, Rashed L. 2012. Serum mannan-binding lectin in egyptian patients with chronic hepatitisC: its relation to disease progression and response to treatment. Hepat Mon, 12: 259-264.
          doi: 10.5812/hepatmon

      8. European Association for the Study of the Liver. 2012. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 57: 167-185.
          doi: 10.1016/j.jhep.2012.02.010

      9. Hoang TV, Toan NL, Song le H, Ouf EA, Bock CT, Kremsner PG, Kun JF, Velavan TP. 2011. ficolin-2 levels and FCN2 haplotypes influence hepatitis B infection outcome in Vietnamese patients. PLoS One, 6: e28113.
          doi: 10.1371/journal.pone.0028113

      10. Holmskov U, Thiel S, Jensenius JC. 2003. Collections and ficolins: humoral lectins of the innate immune defense. Annu RevImmunol, 21.

      11. Honore C, Rorvig S, Hummelshoj T, Skjoedt MO, Borregaard N, Garred P. 2010. Tethering of ficolin-1 to cell surfaces through recognition of sialic acid by the fibrinogen-like domain. J Leukoc Biol, 88: 145-158.
          doi: 10.1189/jlb.1209802

      12. Hu YL, Luo FL, Fu JL, Chen TL, Wu SM, Zhou YD, Zhang XL.2013. Early increased ficolin-2 concentrations are associated with severity of liver inflammation and efficacy of anti-viral therapy in chronic hepatitis C patients. Scand J Immunol, 77:144-150.
          doi: 10.1111/sji.12014

      13. Hummelshoj T, Munthe-Fog L, Madsen HO, Fujita T, Matsushita M, Garred P. 2005. Polymorphisms in the FCN2 gene determine serum variation and function of ficolin-2. Hum Mol Genet, 14:1651-1658.
          doi: 10.1093/hmg/ddi173

      14. Hummelshoj T, Munthe-Fog L, Madsen HO, Garred P. 2008.Functional SNPs in the human ficolin (FCN) genes reveal distinct geographical patterns. Mol Immunol, 45: 2508-2520.
          doi: 10.1016/j.molimm.2008.01.003

      15. Jeong WI, Gao B. 2008. Innate immunity and alcoholic liver fibrosis. J Gastroenterol Hepatol, 23 Suppl 1: S112-118.

      16. Kilpatrick DC, Delahooke TE, Koch C, Turner ML, Hayes PC.2003. Mannan-binding lectin and hepatitis C infection. Scand J Gastroenterol, 132: 92-95.

      17. Li J, Wu W, Peng G, Chen F, Bai M, Zheng M, Chen Z. 2010. HBcAg induces interleukin-10 production, inhibiting HBcAg-specific Th17 responses in chronic hepatitis B patients. Immunol Cell Biol, 88: 834-841.
          doi: 10.1038/icb.2010.63

      18. Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, Xiang T, Tang J, Li D, Hu Q, Ho W, Zhang X. 2009. Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol, 6: 235-244.
          doi: 10.1038/cmi.2009.32

      19. Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M, Wada I, Inoue K, Munakata M, Fujita T. 2005. Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol, 3150-3156.

      20. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Association CM. 2006. Diagnostic and treatment guidelines for liver failure. Zhonghua Gan Zang Bing Za Zhi, 14: 643-646. (In Chinese)

      21. Mannan R, Misra V, Misra SP, Singh PA, Dwivedi M. 2014.A comparative evaluation of scoring systems for assessing necro-inflammatory activity and fibrosis in liver biopsies of patients with chronic viral hepatitis. J Clin Diagn Res, 8: FC08-12.

      22. Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, Ichikawa N, Nakata M, Mizuochi T. 1996. A novel human serum lectin with collagen-and fibrinogen-like domains that functions as an opsonin. J Biol Chem, 271: 2448-2454.
          doi: 10.1074/jbc.271.5.2448

      23. Pan Q, Chen H, Wang F, Jeza VT, Hou W, Zhao Y, Xiang T, Zhu Y, Endo Y, Fujita T. 2012. L-Ficolin Binds to the Glycoproteins Hemagglutinin and Neuraminidase and Inhibits Influenza A Virus Infection Both in vitro and in vivo. J Innate Immun, 4:312-324.
          doi: 10.1159/000335670

      24. Poynard T, Yuen MF, Ratziu V, Lai CL. 2003. Viral hepatitis C. Lancet, 362: 2095-2100.
          doi: 10.1016/S0140-6736(03)15109-4

      25. Ren Y, Ding Q, Zhang X. 2014. Ficolins and infectious diseases. Virol Sin, 29: 25-32.
          doi: 10.1007/s12250-014-3421-2

      26. Song WC, Sarrias MR, Lambris JD. 2000. Complement and innate immunity. Immunopharmacology, 49: 187-198.
          doi: 10.1016/S0162-3109(00)80303-3

      27. Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, Sato H, Hirata J, Okochi K, Izuhara K, Hamasaki N. 1998. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem, 273: 20721-20727.
          doi: 10.1074/jbc.273.33.20721

      28. Walport MJ. 2001. Complement. First of two parts. N Engl J Med, 344: 1058-1066.
          doi: 10.1056/NEJM200104053441406

      29. Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Hai-Jun H. 2013. Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS One, 8: e80585.
          doi: 10.1371/journal.pone.0080585

      30. Zhao Y, Ren Y, Zhang X, Zhao P, Tao W, Zhong J, Li Q, Zhang XL. 2014. ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape. J Immunol, 193: 783-796.
          doi: 10.4049/jimmunol.1302563

    • 加载中

    Figures(6) / Tables(3)

    PDF

    Article Metrics

    Article views(6084) PDF downloads(16) Cited by()

    Related
    Proportional views

      Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases

        Corresponding author: Fengling Luo, fengling810810@163.com
        Corresponding author: Xiao-Lian Zhang, zhangxiaolian@whu.edu.cn
      • 1. State Key Laboratory of Virology and Department of Immunology and Hubei Province Key Laboratory of Allergy and Immunology, Wuhan University School of Medicine, Wuhan 430071, China
      • 2. Zhongnan Hospital of Wuhan University, Wuhan 430071, China
      • 3. Department of Immunology, Wuhan University of Science and Technology School of Medicine, Wuhan 430065, China
      • 4. Hubei Cancer Hospital, Wuhan 430079, China
      • Received Date: 08 May 2015
      • Accepted Date: 13 July 2015
      • Published Date: 23 July 2015

      Abstract: Human ficolin-2 is an important lectin complement pathway activator that is secreted from liver cells and has been implicated as an anti-infection innate immune molecule. However, the role of ficolin-2 protein and its dynamic changes over the course of and in the prognosis of chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC) remain unclear. In this study, we analyzed ficolin-2 protein expression in a cohort of individuals with CHB infection, HCC and cirrhosis. A sandwich enzyme-linked immunosorbent assay (ELISA) method was used to measure serum ficolin-2 concentrations. Ficolin-2 expression in liver tissues was detected by immunohistochemical staining. Serum ficolin-2 concentrations in CHB patients were significantly higher than in healthy controls and HBV carriers. After 48 weeks of routine amelioration liver function treatment, serum ficolin-2 concentrations decreased and were positively correlated with favorable alanine aminotransferase (ALT), HBV DNA and HBeAg-seroconversion outcomes. Interestingly, we observed much lower expression of serum and intrahepatic ficolin-2 in HCC and cirrhosis compared with healthy controls. Our findings suggest that serum and intrahepatic ficolin-2 levels may be considered one of the indicators for the response of chronic HBV infection, HCC and cirrhosis.

        HTML

      INTRODUCTION